News
Wells Fargo raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $91 from $80 and keeps an Overweight rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback